Potential Role of Tranexamic Acid in Rosacea Treatment: conquering Flushing Beyond Melasma
DOI: https://doi.org/10.2147/ccid.s473598
2024-06-15
Clinical Cosmetic and Investigational Dermatology
Abstract:Jiawen Zhang, 1, &ast Duoduo Gu, 2, &ast Yang Yan, 3, &ast Ruoxin Pan, 2 Hui Zhong, 4, 5 Chengfeng Zhang, 1 Yang Xu 2 1 Department of Dermatology, Huashan Hospital of Fudan University, Shanghai, People's Republic of China; 2 Department of Dermatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China; 3 Department of Cardiology, Ren Ji Hospital of Shanghai Jiao Tong University, Shanghai, People's Republic of China; 4 State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China; 5 School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chengfeng Zhang; Yang Xu, Email ; Rosacea is a chronic inflammatory skin disease that affects a patient's appearance and quality of life. It mainly affects the midface region and presents as erythema, flushing, telangiectasia, papules, pustules, and rhinophyma. Despite its prevalence, the precise pathophysiology of rosacea remains unknown, and novel pharmacological therapies are currently under investigation. Tranexamic acid (TA) is a synthetic, lysine-like compound that competitively inhibits fibrinogen production by synthesizing fibrinolytic enzymes. In addition to its popular application in hemorrhage treatment, TA has been used to manage a number of skin conditions, including melasma, chronic urticaria, and angioedema. TA is a better option for melasma treatment. However, the role of TA in treating rosacea has not yet been systematically elucidated. In this study, we reviewed all available literature on the use of TA for rosacea treatment. The included articles examined the therapeutic effects of TA in patients with rosacea, including traditional methods such as oral and topical administration and more novel approaches such as intradermal injections, microneedling, and laser-assisted delivery. Several recent clinical studies demonstrated that TA alleviates rosacea symptoms by restoring the permeability barrier, ameliorating the immune reaction, and inhibiting angiogenesis. In this review, we summarized the function and potential application of TA in rosacea treatment, aiming to facilitate the implementation of clinical applications. Keywords: rosacea, tranexamic acid, topical, oral, microinjection Rosacea is a chronic inflammatory dermatosis characterized by symmetric erythema, with or without flushing, mainly affecting the midface region. Clinical manifestations of rosacea include recurrent transient or persistent erythema, paroxysmal flushing, telangiectasia, papules, pustules, and rhinophyma. Patients with rosacea may also experience discomfort owing to skin irritation, dryness, and burning. Areas of erythema and flushing involve the bilateral forehead, cheeks, nose, chin, and ears. Rosacea mostly affects women aged between 30 and 50 years, 1 and its worldwide prevalence ranges from 1% to 22%. 2 The precise pathogenesis of rosacea remains unclear, with hypotheses that it could be associated with genetic background, abnormal innate and adaptive immunity, dysregulated neurovascular system, impaired skin barrier function, and an altered microbiome. 3–6 The most common triggers are sun exposure, emotional pressure, temperature changes, and hot weather. 7 In rosacea, several molecules related to innate immunity, including toll-like receptor 2, serine proteinase kallikrein 5 (KLK5), and cathelicidin, are overexpressed. 8 The dermis is infiltrated by immunocytes, including mast cells, macrophages, neutrophils, and lymphocytes, and dilated vessels are observed. Considering the aforementioned pathogenesis, a series of topical and systemic medications are available for different targets. Among topical drugs, KLK5 inhibitors, including ivermectin 9 and azelaic acid, 10 selective adrenoreceptor agonists, including brimonidine and oxymetazoline, and demodex inhibitors, such as metronidazole, are most commonly used. 11 Among systemic medications, doxycycline inhibits the activation of KLKs, 12 and isotretinoin and selective beta-adrenergic receptor blockers are commonly used. 11,13 In addition, intense pulsed light has been reported to be associated with decreased expression of KLK5, inhibiting mast cell degranulation and alleviating the clinical manifestations of rosacea. 14 However, post-inflammatory pigmentation may occur in patients with rosacea after the alleviation of clinical manifestations. Therefore, optimized treatment to effectively target both inflamm -Abstract Truncated-
dermatology